Benzinga's M&A Chatter for Monday February 3, 2014
Benzinga 12 years ago
NewsM&AMovers
The following are the M&A deals, rumors and chatter circulating on Wall Street for Monday February 3, 2014:
Smith & Nephew To Acquire ArthroCare for $48.25/share in Cash
The Deal:
Smith & Nephew (NYSE: SNN) announced Monday an agreement to acquire medical device company ArthroCare (NASDAQ: ARTC) for $48.25 per ArthroCare share in cash. Total consideration is approximately $1.7 billion, with an enterprise value of $1.5 billion. The deal is expected to close in mid-2014. Smith & Nephew closed Monday at $72.06, a loss of $0.18, while ArthroCare gained 8%, closing at $49.12. Valeant Pharmaceuticals to Acquire Precision Dermatology for $475M The Deal:
Valeant Pharmaceuticals (NYSE: VRX) announced Monday that it will acquire PreCision Dermatology for $475 million in cash, plus an additional milestone payment of $25 million. The deal is expected to close in H1 2014. Valeant Pharmaceuticals closed Monday at $133.36, a loss of 1.5% Altria Announces Agreement to Acquire E-Vapor Business of Green Smoke for $110M in Cash The Deal:
Altria Group (NYSE: MO) announced Monday that its subsidiary, Nu Mark will acquire the e-vapor business of Green Smoke and its affiliates for approximately $110 million in cash, plus up to $20 million in incentive payments. The deal is expected to close in Q2 2014. Altria Group closed Monday at $34.11, a loss of 3%.
Smith & Nephew (NYSE: SNN) announced Monday an agreement to acquire medical device company ArthroCare (NASDAQ: ARTC) for $48.25 per ArthroCare share in cash. Total consideration is approximately $1.7 billion, with an enterprise value of $1.5 billion. The deal is expected to close in mid-2014. Smith & Nephew closed Monday at $72.06, a loss of $0.18, while ArthroCare gained 8%, closing at $49.12. Valeant Pharmaceuticals to Acquire Precision Dermatology for $475M The Deal:
Valeant Pharmaceuticals (NYSE: VRX) announced Monday that it will acquire PreCision Dermatology for $475 million in cash, plus an additional milestone payment of $25 million. The deal is expected to close in H1 2014. Valeant Pharmaceuticals closed Monday at $133.36, a loss of 1.5% Altria Announces Agreement to Acquire E-Vapor Business of Green Smoke for $110M in Cash The Deal:
Altria Group (NYSE: MO) announced Monday that its subsidiary, Nu Mark will acquire the e-vapor business of Green Smoke and its affiliates for approximately $110 million in cash, plus up to $20 million in incentive payments. The deal is expected to close in Q2 2014. Altria Group closed Monday at $34.11, a loss of 3%.